 The aim of the study is to determine tumor uptake of 68Ga-DOTANOC in patients with non-Hodgkins and Hodgkins lymphoma to characterize the SST2, SST3 and SST5 receptor status of the tumour in vivo with 68Ga-DOTANOC PETCT. In addition, immunohistochemical analysis of SST2, SST3 and SST5 subtype status will be made of the tumor specimens obtained in routine diagnostic biopsy resection. Furthermore, PET findings will be correlated with advanced MRI techniques, such as diffusion weighted imaging DWI in an attempt to find methods which limit radiation exposure especially in young patients. Hence, PETCT will be performed with 68Ga-DOTANOC and 18F-FDG and compared with whole-body MRI including DWI to define the most sensitive and specific imaging method appropriate for routine diagnosis and follow-up of patients with lymphoma. 